Coherence

Coherence operates at the intersection of therapeutic brain-computer interfaces, oncology, and bioelectronics rather than competing solely in conventional digital health or neuromodulation. Its SOMA platform is designed to combine a small implant, wireless wearable, continuous neural recording, adaptive electrical stimulation, and software-based data analysis for cancer management. That combination creates a differentiated thesis: using neural signals and stimulation as part of an oncology treatment loop, initially focusing on glioblastoma, instead of positioning the device primarily as an assistive interface or general neurological therapy. Neuralink and Synchron are useful technology comparators in implantable brain-computer interfaces, while companies such as ONWARD Medical represent adjacent work in therapeutic neurostimulation. Coherence’s claimed differentiation is the application of these capabilities to cancer biology and treatment, including the use of real-time biological signals and AI-enabled analysis. The company remains earlier in clinical and commercial maturity than established neuromodulation businesses. Its reported three-patient test in June 2026 and $10 million seed round in November 2025 provide evidence of advancing development, but public information does not yet establish efficacy, regulatory clearance, reimbursement, or repeatable clinical adoption. The Cambridge base, U.S. expansion, and SPARCLE participation give it an international research profile, while its small disclosed team underscores its still-emerging market position.

Coherence’s trajectory shows a rapid progression from formation in 2022 to early clinical testing by 2026. The company raised a $2.25 million pre-seed round on March 13, 2023, followed by a substantially larger $10 million seed round on November 3, 2025, representing more than four times the earlier financing and bringing cumulative funding to $12.25 million. The seed capital coincided with a clearer product and financing narrative around a closed-loop neurotechnology system for cancer treatment. Product development has expanded into a coordinated SOMA ecosystem: a coin-sized implant, an over-ear wearable, a mobile application, and an AI-enabled data layer for neural signal interpretation and adaptive stimulation. A June 23, 2026 report that the implant had been tested in three patients is the clearest disclosed inflection point from engineering and preclinical work toward human clinical experience. Geographic expansion also matters: the company reported plans for a San Francisco office and in vivo facility during 2025, complementing its Cambridge base and international research activity. The €11.5 million SPARCLE Consortium announced in July 2025 adds collaborative infrastructure and visibility.